One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study

OBJECTIVE: To assess efficacy and tolerability of 1-year erenumab treatment in patients with episodic migraine. METHODS: Patients were randomized (n = 955; 1:1:1) during the 24-week double-blind treatment phase (DBTP) to monthly subcutaneous placebo or erenumab 70 or 140 mg. At week 24, 845 patients...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Neurology
Главные авторы: Goadsby, Peter J., Reuter, Uwe, Hallström, Yngve, Broessner, Gregor, Bonner, Jo H., Zhang, Feng, Wright, Ian K., Chou, Denise E., Klatt, Jan, Picard, Hernan, Lenz, Robert A., Mikol, Daniel D.
Формат: Artigo
Язык:Inglês
Опубликовано: Lippincott Williams & Wilkins 2020
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7455346/
https://ncbi.nlm.nih.gov/pubmed/32636324
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0000000000010019
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы